Baxter, Takeda deal

Takeda received exclusive, Japanese rights to use Baxter's Vero cell culture technology to develop influenza vaccines. The companies also plan to co-develop an H5N1 influenza vaccine in Japan. Baxter will receive upfront payments and development cost reimbursements and will be eligible for milestones and royalties. Clinical testing of the vaccine is expected to start next year. Further terms were not disclosed. ...